

# Hiroyuki Gatanaga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2008264/publications.pdf>

Version: 2024-02-01

70  
papers

1,888  
citations

304743

22  
h-index

276875

41  
g-index

72  
all docs

72  
docs citations

72  
times ranked

2817  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of asymptomatic <i>Entamoeba histolytica</i> infection by a serological screening test: A cross-sectional study of an HIV-negative men who have sex with men cohort in Japan. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0009793.	3.0	4
2	High prevalence of circulating dual-class resistant <i>Mycoplasma genitalium</i> in asymptomatic MSM in Tokyo, Japan. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab091.	2.1	13
3	Performance of an enzyme-linked immunosorbent-based serological assay for <i>Entamoeba histolytica</i> : Comparison with an indirect immunofluorescence assay using stored frozen samples. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 736-739.	1.7	3
4	Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus. <i>International Journal of Infectious Diseases</i> , 2021, 110, 21-28.	3.3	19
5	Modified self-obtained pooled sampling to screen for <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> infections in men who have sex with men. <i>Sexually Transmitted Infections</i> , 2021, 97, 324-328.	1.9	9
6	Seroprevalence of <i>Entamoeba histolytica</i> at a voluntary counselling and testing centre in Tokyo: a cross-sectional study. <i>BMJ Open</i> , 2020, 10, e031605.	1.9	10
7	Full-genome analysis of hepatitis C virus in HIV-coinfected hemophilic Japanese patients. <i>Hepatology Research</i> , 2020, 50, 763-769.	3.4	1
8	Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up. <i>Global Health &amp; Medicine</i> , 2020, 2, 9-17.	1.4	6
9	Title is missing!. , 2020, 16, e1009177.		0
10	Title is missing!. , 2020, 16, e1009177.		0
11	Title is missing!. , 2020, 16, e1009177.		0
12	Title is missing!. , 2020, 16, e1009177.		0
13	Comment on: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3402-3403.	3.0	1
14	High prevalence and incidence of rectal <i>Chlamydia</i> infection among men who have sex with men in Japan. <i>PLoS ONE</i> , 2019, 14, e0220072.	2.5	11
15	Full-Genome Analysis of Hepatitis C Virus in Japanese and Non-Japanese Patients Coinfected With HIV-1 in Tokyo. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 350-357.	2.1	8
16	Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 549-554.	1.7	12
17	Induction of IFN- $\gamma$ as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. <i>Gut</i> , 2018, 67, 362-371.	12.1	144
18	Time to development of ocular syphilis after syphilis infection. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 75-77.	1.7	14

#	ARTICLE	IF	CITATIONS
19	Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study. <i>BMC Cancer</i> , 2018, 18, 1066.	2.6	27
20	Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control. <i>EBioMedicine</i> , 2018, 36, 103-112.	6.1	10
21	Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection. <i>Aids</i> , 2017, 31, 1935-1943.	2.2	7
22	Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors. <i>PLoS ONE</i> , 2017, 12, e0177033.	2.5	10
23	Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. <i>PLoS ONE</i> , 2017, 12, e0186255.	2.5	13
24	HIV-1 Control by NK Cells via Reduced Interaction between KIR2DL2 and HLA-C $\alpha$ 12:02/C $\alpha$ 14:03. <i>Cell Reports</i> , 2016, 17, 2210-2220.	6.4	27
25	Effects of a Single Escape Mutation on T Cell and HIV-1 Co-adaptation. <i>Cell Reports</i> , 2016, 15, 2279-2291.	6.4	19
26	Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2760-2766.	3.0	6
27	Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals. <i>Retrovirology</i> , 2015, 12, 98.	2.0	4
28	Routine Eye Screening by an Ophthalmologist Is Clinically Useful for HIV-1-Infected Patients with CD4 Count Less than 200 $\mu$ L. <i>PLoS ONE</i> , 2015, 10, e0136747.	2.5	27
29	Prevalence of Anal Human Papillomavirus Infection and Risk Factors among HIV-positive Patients in Tokyo, Japan. <i>PLoS ONE</i> , 2015, 10, e0137434.	2.5	27
30	A 21-Day of Adjunctive Corticosteroid Use May Not Be Necessary for HIV-1-Infected Pneumocystis Pneumonia with Moderate and Severe Disease. <i>PLoS ONE</i> , 2015, 10, e0138926.	2.5	5
31	What Triggers a Diagnosis of HIV Infection in the Tokyo Metropolitan Area? Implications for Preventing the Spread of HIV Infection in Japan. <i>PLoS ONE</i> , 2015, 10, e0143874.	2.5	9
32	HIV-1 infection, but not syphilis or HBV infection, is a strong risk factor for anorectal condyloma in Asian population: A prospective colonoscopy screening study. <i>International Journal of Infectious Diseases</i> , 2015, 37, 70-76.	3.3	4
33	Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections. <i>Journal of Virology</i> , 2015, 89, 7363-7372.	3.4	5
34	High-Dose Oral Amoxicillin Plus Probenecid Is Highly Effective for Syphilis in Patients With HIV Infection. <i>Clinical Infectious Diseases</i> , 2015, 61, 177-183.	5.8	49
35	Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes. <i>Journal of Virology</i> , 2015, 89, 5330-5339.	3.4	56
36	Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study. <i>PLoS ONE</i> , 2015, 10, e0141931.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e87596.	2.5	42
38	Acute Hepatitis C in HIV-1 Infected Japanese Cohort: Single Center Retrospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e100517.	2.5	18
39	Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3320-3328.	3.0	15
40	Clinical Significance of High Anti-Entamoeba histolytica Antibody Titer in Asymptomatic HIV-1-infected Individuals. <i>Journal of Infectious Diseases</i> , 2014, 209, 1801-1807.	4.0	24
41	Clinical Importance of Hyper-Beta-2-Microglobulinuria in Patients With HIV-1 Infection on Tenofovir-Containing Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e155-e157.	2.1	3
42	Selection of T18-8V Mutant Associated with Long-Term Control of HIV-1 by Cross-Reactive HLA-B*51:01-Restricted Cytotoxic T Cells. <i>Journal of Immunology</i> , 2014, 193, 4814-4822.	0.8	11
43	Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted HIV-1-specific CTL recognition. <i>Microbes and Infection</i> , 2014, 16, 434-438.	1.9	1
44	Asymptomatic Intestinal Amebiasis in Japanese HIV-1-Infected Individuals. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 816-820.	1.4	10
45	Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 784-788.	1.7	13
46	Superimposed Epitopes Restricted by the Same HLA Molecule Drive Distinct HIV-Specific CD8+ T Cell Repertoires. <i>Journal of Immunology</i> , 2014, 193, 77-84.	0.8	15
47	Host-Specific Adaptation of HIV-1 Subtype B in the Japanese Population. <i>Journal of Virology</i> , 2014, 88, 4764-4775.	3.4	47
48	Skin rash induced by ritonavir-boosted darunavir is common, but generally tolerable in an observational setting. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 285-287.	1.7	8
49	Incidence and Risk Factors for Incident Hepatitis C Infection Among Men Who Have Sex With Men With HIV-1 Infection in a Large Urban HIV Clinic in Tokyo. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 213-217.	2.1	58
50	Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular Immunity. <i>Clinical Infectious Diseases</i> , 2013, 57, 1051-1055.	5.8	22
51	Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection. <i>Clinical Infectious Diseases</i> , 2013, 56, 1812-1819.	5.8	61
52	Distinct HIV-1 Escape Patterns Selected by Cytotoxic T Cells with Identical Epitope Specificity. <i>Journal of Virology</i> , 2013, 87, 2253-2263.	3.4	30
53	Reply to Sheng et al. <i>Clinical Infectious Diseases</i> , 2013, 57, 1506-1506.	5.8	10
54	Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naïve Patients with Advanced HIV-1 Infection in the HAART Era. <i>PLoS ONE</i> , 2013, 8, e65348.	2.5	15

#	ARTICLE	IF	CITATIONS
55	Illicit Drug Use Is a Significant Risk Factor for Loss to Follow Up in Patients with HIV-1 Infection at a Large Urban HIV Clinic in Tokyo. <i>PLoS ONE</i> , 2013, 8, e72310.	2.5	13
56	Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients. <i>PLoS ONE</i> , 2013, 8, e77268.	2.5	17
57	Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?. <i>PLoS ONE</i> , 2013, 8, e69845.	2.5	10
58	High Prevalence of Illicit Drug Use in Men Who Have Sex with Men with HIV-1 Infection in Japan. <i>PLoS ONE</i> , 2013, 8, e81960.	2.5	17
59	HLA Class I-Mediated Control of HIV-1 in the Japanese Population, in Which the Protective HLA-B*57 and HLA-B*27 Alleles Are Absent. <i>Journal of Virology</i> , 2012, 86, 10870-10872.	3.4	40
60	High Incidence of Renal Stones Among HIV-Infected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor-Containing Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2012, 55, 1262-1269.	5.8	80
61	Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Na <sup>+</sup> ve Patients with HIV Infection. <i>PLoS ONE</i> , 2012, 7, e29977.	2.5	54
62	Selection of escape mutant by HLA-B*57-restricted HIV-1 Pol-specific cytotoxic T lymphocytes carrying strong ability to suppress HIV-1 replication. <i>European Journal of Immunology</i> , 2011, 41, 97-106.	2.9	26
63	Effective recognition of HIV-1-infected cells by HIV-1 integrase-specific HLA-B*4002-restricted T cells. <i>Microbes and Infection</i> , 2011, 13, 160-166.	1.9	10
64	Amebiasis in HIV-1-Infected Japanese Men: Clinical Features and Response to Therapy. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1318.	3.0	56
65	Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance. <i>Aids</i> , 2010, 24, F15-F22.	2.2	13
66	Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: Nationwide surveillance from 2003 to 2008 in Japan. <i>Antiviral Research</i> , 2010, 88, 72-79.	4.1	50
67	Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but Not Etravirine. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1596-1602.	3.2	31
68	Adaptation of HIV-1 to human leukocyte antigen class I. <i>Nature</i> , 2009, 458, 641-645.	27.8	408
69	Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. <i>Antiviral Research</i> , 2007, 75, 75-82.	4.1	46
70	Altered HIV-1 Gag Protein Interactions with Cyclophilin A (CypA) on the Acquisition of H219Q and H219P Substitutions in the CypA Binding Loop. <i>Journal of Biological Chemistry</i> , 2006, 281, 1241-1250.	3.4	47